Benzaldehyde Intermediate Synthesis With Mild Deprotection Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (Compound (I)) suffer from unwanted polymerization and decomposition reactions during deprotection processes, leading to complex mixtures and low yields, making them impractical for commercial scale production.

Innovation Solution

A process involving protecting groups and mild reaction conditions, including the use of specific acids and solvents, followed by crystallization in heptane and methyl tert-butyl ether, is employed to suppress polymerization and decomposition, enabling commercial scale synthesis of Compound (I).

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional deprotection processes are used to synthesize Compound (I), then the hydroxyl groups can be deprotected, but unwanted polymerization and decomposition reactions occur leading to complex mixtures and low yields

Engineering Contradiction:
Improvepurity of Compound (I)VSAvoidpolymerization and decomposition reactions
Core Design Contradiction:
Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

The patent applies preliminary protection of hydroxyl groups with specific protecting groups (such as silyl protecting groups like TBS or TIPS) before performing formylation and other reactions. This preliminary action prevents polymerization and decomposition of the aldehyde group during subsequent reaction steps, enabling clean synthesis of Compound (I) with high purity and yield.

Inventive Principle:
Principle #10Preliminary action

2Ease of manufacture

If conventional deprotection conditions are used, then deprotection of hydroxyl groups can be achieved, but significant effort is required to purify Compound (I) to acceptable degrees

Engineering Contradiction:
Improveease of purificationVSAvoidpurity of Compound (I)
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent employs specific parameter changes in the deprotection step, using mild acidic conditions (such as TFA in dichloromethane or acetic acid in water) at controlled temperatures and pH levels. These parameter changes enable selective deprotection of the hydroxyl groups without causing polymerization or decomposition, significantly simplifying the purification process while maintaining high product purity.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If scale up of manufacturing is attempted with conventional processes, then production volume can be increased, but physical properties and purity of Compound (I) are impacted

Engineering Contradiction:
Improveproduction volume of Compound (I)VSAvoidpurity and physical properties of Compound (I)
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent segments the synthesis into distinct, optimized steps with specific protecting group strategies for each stage. The multi-step synthesis with controlled protection and deprotection sequences can be independently optimized and scaled, allowing large-scale production while maintaining consistent product quality, purity, and physical properties through standardized operating procedures at each stage.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process significantly reduces polymerization and decomposition reactions, increasing purity and yield, allowing for large-scale production of Compound (I) with improved physical properties and cost-effectiveness.

Implementation Method 1

Compound (I) binds to hemoglobin and increases it oxygen affinity

Methodology Applied
Scientific EffectOxygen binding: Absorption (physical)

Implementation Method 2

crystallizing Compound (I) from heptane and methyl tert-butyl ether at 40° +/-5 °C to 55 +/-5 °C

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Data Source

PatentEP3909941B1Intermediates of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
Publication Date: 2026.04.15 GLOBAL BLOOD THERAPEUTICS INC
  • EP3909941B1 patent drawingFigure 1
  • EP3909941B1 patent drawingFigure 2
  • EP3909941B1 patent drawing

AI summary

Disclosed herein are synthetic intermediates in a process for synthesizing 2-hydroxy-6-((2-(l-isopropyl-lH- pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde.